[8-K] CRISPR Therapeutics AG Reports Material Event

Rhea-AI Filing Summary

Simulations Plus, Inc. (SLP) – Form 4 insider filing

Director Lisa LaVange disclosed two transactions on 08/01/2025:

• Equity grant: 2,074 common shares awarded under the 2021 Equity Incentive Plan at a deemed price of $0, lifting her stake to 10,797 shares.
• Rule 10b5-1 sale: 867 common shares sold at $12.93 per share in a single automatic trade, trimming direct ownership to 9,930 shares.

No derivative securities were involved, and the filing was executed by attorney-in-fact Daniel Hoeft on 08/04/2025.

Insights

Securities Analyst

TL;DR: Minor director sale offset by stock grant; negligible net ownership change—impact appears neutral.

The filing shows Ms. LaVange received 2,074 shares as routine board compensation and subsequently sold 867 shares at $12.93 via a pre-set Rule 10b5-1 plan. Post-trade direct holdings stand at 9,930 shares, down only 8% from the intra-day peak of 10,797. No derivatives or unusual activity are reported. Given the modest size relative to her total stake and lack of material information about company operations, the market impact should be limited.

0001674416false00-000000000016744162025-08-042025-08-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2025

CRISPR THERAPEUTICS AG

(Exact name of registrant as specified in its charter)

Switzerland			001-37923	Not Applicable
(State or other jurisdiction of incorporation)			(Commission File Number)	(IRS Employer Identification No.)
Baarerstrasse 14
6300 Zug, Switzerland				Not Applicable
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: 41 (0)41 561 32 77

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, nominal value CHF 0.03		CRSP		The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 2.02 Results of Operations and Financial Condition.

On August 4, 2025, CRISPR Therapeutics AG announced its financial results for the quarter ended June 30, 2025 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

Exhibit No.		Description
99.1		Press Release by CRISPR Therapeutics AG, dated August 4, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			CRISPR Therapeutics AG
Date:	August 4, 2025	By:	/s/ Samarth Kulkarni
			Samarth Kulkarni, Ph.D. Chief Executive Officer

FAQ

How many Simulations Plus (SLP) shares did Director Lisa LaVange receive?

She was granted 2,074 common shares under the 2021 Equity Incentive Plan.

What price did LaVange sell her SLP shares for?

The 867 shares were sold in a single transaction at $12.93 per share.

How many SLP shares does LaVange own after the transactions?

Her direct beneficial ownership stands at 9,930 common shares.

Were the sales made under a Rule 10b5-1 trading plan?

Yes. The filing states the sale was automatically executed pursuant to a Rule 10b5-1 plan.

Did the Form 4 report any derivative securities for SLP?

No. No derivative securities were reported in this filing.